Katharine K Brewster1,2, Martina Pavlicova3, Alexandra Stein1,2, Mei Chen2, Chen Chen2, Patrick J Brown1,2, Steven P Roose1,2, Ana H Kim1,4, Justin S Golub1,4, Adam Brickman1,5, Jessica Galatioto1,4, Megan Kuhlmey1,4, Bret R Rutherford1,2. 1. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA. 2. New York State Psychiatric Institute, New York, New York, USA. 3. Columbia University Mailman School of Public Health, New York, New York, USA. 4. Columbia University Department of Otolaryngology-Head and Neck Surgery, New York, New York, USA. 5. Taub Institute for Research on Alzheimer's Disease and the Aging Brain and Department of Neurology, New York, New York, USA.
Abstract
OBJECTIVES: Age-related hearing loss (ARHL) is a prevalent condition associated with increased risk for depression and cognitive decline. This 12-week prospective, double-blind pilot randomized controlled trial (RCT) of hearing aids (HAs) for depressed older adults with ARHL evaluated the feasibility of a novel research design. METHODS/ DESIGN: N = 13 individuals aged ≥60 years with Major Depressive Disorder or Persistent Depressive Disorder and at least mild hearing loss (pure tone average≥ 30 dB) were randomized to receive full- (active) vs low-amplification (sham) HAs added to psychiatric treatment as usual. Duration of HA use in hours/day, adverse events frequency, attrition rate, and maintenance of the study blinding were the primary outcome measures. RESULTS: Compliance with HAs was excellent (>9 hours/day for both groups) and rates of adverse events and drop-outs did not differ between groups. Preliminary data demonstrated differential improvement for active vs sham HAs on hearing functioning (Hearing Handicap Inventory for the Elderly [nonparametric effect size (np-ES) = 0.62]), depressive symptoms (Inventory for Depressive Symptomatology [np-ES = 0.31]), cognition (Repeatable Battery for the Assessment of Neuropsychological Status Immediate Memory [np-ES = 0.25]), and general functioning (World Health Organization Disability Assessment Schedule [np-ES = 0.53]). Significantly greater than 50% of both groups correctly guessed their treatment assignment, indicating incomplete concealment of treatment allocation. CONCLUSIONS: This pilot RCT for ARHL and late-life depression was feasible to execute and showed clinical promise, but improved methods of blinding the experimental treatments are needed. Larger studies should investigate whether hearing remediation may be an effective preventative and/or therapeutic strategy for late-life depression and cognitive decline.
RCT Entities:
OBJECTIVES:Age-related hearing loss (ARHL) is a prevalent condition associated with increased risk for depression and cognitive decline. This 12-week prospective, double-blind pilot randomized controlled trial (RCT) of hearing aids (HAs) for depressed older adults with ARHL evaluated the feasibility of a novel research design. METHODS/ DESIGN: N = 13 individuals aged ≥60 years with Major Depressive Disorder or Persistent Depressive Disorder and at least mild hearing loss (pure tone average ≥ 30 dB) were randomized to receive full- (active) vs low-amplification (sham) HAs added to psychiatric treatment as usual. Duration of HA use in hours/day, adverse events frequency, attrition rate, and maintenance of the study blinding were the primary outcome measures. RESULTS: Compliance with HAs was excellent (>9 hours/day for both groups) and rates of adverse events and drop-outs did not differ between groups. Preliminary data demonstrated differential improvement for active vs sham HAs on hearing functioning (Hearing Handicap Inventory for the Elderly [nonparametric effect size (np-ES) = 0.62]), depressive symptoms (Inventory for Depressive Symptomatology [np-ES = 0.31]), cognition (Repeatable Battery for the Assessment of Neuropsychological Status Immediate Memory [np-ES = 0.25]), and general functioning (World Health Organization Disability Assessment Schedule [np-ES = 0.53]). Significantly greater than 50% of both groups correctly guessed their treatment assignment, indicating incomplete concealment of treatment allocation. CONCLUSIONS: This pilot RCT for ARHL and late-life depression was feasible to execute and showed clinical promise, but improved methods of blinding the experimental treatments are needed. Larger studies should investigate whether hearing remediation may be an effective preventative and/or therapeutic strategy for late-life depression and cognitive decline.
Authors: Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang Journal: Alzheimers Dement Date: 2014-07-09 Impact factor: 21.566
Authors: Rebecca J Kamil; Joshua Betz; Becky Brott Powers; Sheila Pratt; Stephen Kritchevsky; Hilsa N Ayonayon; Tammy B Harris; Elizabeth Helzner; Jennifer A Deal; Kathryn Martin; Matthew Peterson; Suzanne Satterfield; Eleanor M Simonsick; Frank R Lin Journal: J Aging Health Date: 2015-10-05
Authors: Bret R Rutherford; Katharine Brewster; Justin S Golub; Ana H Kim; Steven P Roose Journal: Am J Psychiatry Date: 2017-12-05 Impact factor: 18.112
Authors: Nicholas S Reed; Aylin Altan; Jennifer A Deal; Charlotte Yeh; Alexander D Kravetz; Margaret Wallhagen; Frank R Lin Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-01-01 Impact factor: 6.223
Authors: Bret R Rutherford; Melanie M Wall; Patrick J Brown; Tse-Hwei Choo; Tor D Wager; Bradley S Peterson; Sarah Chung; Irving Kirsch; Steven P Roose Journal: Am J Psychiatry Date: 2016-09-09 Impact factor: 18.112
Authors: Annes J Claes; Griet Mertens; Annick Gilles; Anouk Hofkens-Van den Brandt; Erik Fransen; Vincent Van Rompaey; Paul Van de Heyning Journal: Front Neurosci Date: 2016-11-15 Impact factor: 4.677
Authors: Katharine Brewster; C Jean Choi; Xiaofu He; Ana H Kim; Justin S Golub; Patrick J Brown; Ying Liu; Steven P Roose; Bret R Rutherford Journal: Am J Geriatr Psychiatry Date: 2021-08-14 Impact factor: 4.105
Authors: Franchesca Arias; Margarita Alegria; Amy J Kind; Richard N Jones; Thomas G Travison; Edward R Marcantonio; Eva M Schmitt; Tamara G Fong; Sharon K Inouye Journal: J Am Geriatr Soc Date: 2021-10-25 Impact factor: 5.562
Authors: Danielle S Powell; Esther S Oh; Nicholas S Reed; Frank R Lin; Jennifer A Deal Journal: Front Aging Neurosci Date: 2022-02-28 Impact factor: 5.702